FSHD / OPMD / MYOTONIC DYSTROPHY: P.229 Open-Label study of losmapimod evaluating safety, tolerability, and changes in biomarker and clinical outcome assessments in subjects with FSHD1

M. Mellion, J. Kools, K. Mul, L. Ronco, A. Odueyungbo, K. Marshall, B. van Engelen, D. Cadavid

Neuromuscular Disorders（2020）

Cited 0|Views2

No score

Abstract

s / Neuromuscular Disorders 30 (2020) S46–S150 S113 P.229 Open-Label study of losmapimod evaluating safety, tolerability, and changes in biomarker and clinical outcome assessments in subjects with FSHD1 M. Mellion 1 , J. Kools 2 , K. Mul 2 , L. Ronco 1 , A. Odueyungbo 1 , K. Marshall 1 , B. van Engelen 2 , D. Cadavid 1 1 Fulcrum Therapeutics, Cambridge, USA; 2 Radboudumc, Nijmegen,

Translated text

Key words

opmd

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined